Emerging Biopharma

>

Latest News

AbbVie Acquires Capstan Therapeutics in $2.1 Billion Deal
AbbVie Acquires Capstan Therapeutics in $2.1 Billion Deal

June 30th 2025

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase I development for B cell-mediated autoimmune diseases.

UAE flag waving in the sky, national symbol of UAE | Image Credit: © Freelancer - stock.adobe.com
Abu Dhabi Reinforces Global Leadership in Healthcare Innovation with High-Level US Visit

June 20th 2025

Eli Lilly to Acquire Verve Therapeutics for $1 Billion
Eli Lilly to Acquire Verve Therapeutics for $1 Billion

June 17th 2025

Sanofi Expands Neurology Portfolio with $470 Million Acquisition of Vigil Neuroscience
Sanofi Expands Neurology Portfolio with $470 Million Acquisition of Vigil Neuroscience

May 22nd 2025

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers
Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

May 20th 2025

More News

Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic Health

Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic Health

Don Tracy, Associate Editor
January 22nd 2025

The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.

Teva Agrees to Strategic Partnerships with Formycon AG, Klinge Biopharma, & Samsung Bioepis

Teva Agrees to Strategic Partnerships with Formycon AG, Klinge Biopharma, & Samsung Bioepis

Don Tracy, Associate Editor
January 14th 2025

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

<12